Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins (Q39690739)

14 September 2017

Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins (English)

1 reference

14 September 2017

squamous cell carcinoma

1 reference

T T Zhao

1

1 reference

14 September 2017

B G Le Francois

2

1 reference

14 September 2017

G Goss

3

1 reference

14 September 2017

K Ding

4

1 reference

14 September 2017

P A Bradbury

5

1 reference

14 September 2017

J Dimitroulakos

6

1 reference

14 September 2017

language of work or name

English

0 references

publication date

21 June 2010

1 reference

14 September 2017

1 reference

14 September 2017

29

1 reference

14 September 2017

33

1 reference

14 September 2017

4682-4692

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2010.219

14 September 2017

0 references

cites work

Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

[mTOR inhibitors: pleiotropic antiproliferative drugs].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Regulation and functions of Rho-associated kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Activating transcription factor 4 is translationally regulated by hypoxic stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Monitoring the cellular effects of HMG-CoA reductase inhibitors in vitro and ex vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Pharmacology of competitive inhibitors of HMG-CoA reductase.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

The amino acid sensitive TOR pathway from yeast to mammals.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Molecular characterization of the effects of Y-27632.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Regulation of the mevalonate pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

31 March 2020

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

ZD1839: targeting the epidermal growth factor receptor in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Requirement of cortical actin organization for bombesin, endothelin, and EGF receptor internalization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

The EGF receptor family as targets for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

EGFR and cancer prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Activation of the integrated stress response regulates lovastatin-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Re-localization of activated EGF receptor and its signal transducers to multivesicular compartments downstream of early endosomes in response to EGF.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Ras and Rho regulation of the cell cycle and oncogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Single-molecule imaging of EGFR signalling on the surface of living cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Rab GTPases, intracellular traffic and disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Inhibitors of prenyl transferases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Erlotinib in previously treated non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.219

31 March 2020

Identifiers

DOI

10.1038/ONC.2010.219

1 reference

14 September 2017

1 reference